BUZZ - Snap shares fall as revenue misses expectations and user metrics change
路透社2026/11/05 10:51November 5 - ** Snap ( SNAP.N ), the operator of Snapchat, saw its share price fall 9.8% in pre-market trading to $5.34
** The company’s third-quarter revenue (link) missed analysts’ expectations, with advertising revenue growing by 4%, lower than the company’s forecast
** CEO Evan Spiegel attributed this to reduced consumer spending caused by macroeconomic pressures in the US and Middle East
** B Riley (maintains a "Buy" rating, lowers target price from $10 to $8) believes that the company using monthly active users (MAU) instead of daily active users (DAU) as an audience metric means a loss of insight into regional engagement data
** Among 44 analysts, 31 have an average rating of "Hold", 9 rate it "Buy", 1 gives a "Strong Buy", and 3 rate it "Sell"; the median target price is $6.88 — according to LSEG compiled data
** As of the previous trading day’s close, the stock was down nearly 27% for the year
(To assist non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to possible errors in automated translation or lack of required context, Reuters does not guarantee the accuracy of the translated texts, which are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Crypto prices
More
